Vigil Neuroscience Inc.

AI Score

0

Unlock

1.89
0.11 (6.18%)
At close: Jan 15, 2025, 12:31 PM
undefined%
Bid 1.87
Market Cap 77.25M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.07
PE Ratio (ttm) -0.91
Forward PE n/a
Analyst Buy
Ask 1.89
Volume 82,347
Avg. Volume (20D) 240,950
Open 1.82
Previous Close 1.78
Day's Range 1.80 - 1.95
52-Week Range 1.49 - 6.06
Beta undefined

About VIGL

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy wi...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 7, 2022
Employees 64
Stock Exchange NASDAQ
Ticker Symbol VIGL

Analyst Forecast

According to 5 analyst ratings, the average rating for VIGL stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 931.86% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
6 months ago · Source
-10.02%
Vigil Neuroscience shares are trading lower. The c... Unlock content with Pro Subscription
6 months ago · Source
+18.52%
Vigil Neuroscience shares are trading higher after Sanofi made a $40 million investment in the company.